Faron Pharmaceuticals Oy – Trademark Portfolio
Entity Type: 09
Faron Pharmaceuticals Oy holds 13 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 12 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 3 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include FARON, BEXCLEVY, BEXIGNUS, and HAEMATOKINE.
Joukahaisenkatu 6
FI-20520 Turku
Showing of trademarks Trademarks
Trademark Classifications
Faron Pharmaceuticals Oy's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Faron Pharmaceuticals Oy have?
Faron Pharmaceuticals Oy has 13 U.S. trademarks filed with the USPTO. Of these, 4 registered, 9 cancelled.
What trademark classes does Faron Pharmaceuticals Oy file in?
Faron Pharmaceuticals Oy files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Faron Pharmaceuticals Oy's most well-known trademarks?
Faron Pharmaceuticals Oy's registered trademark portfolio includes well-known marks such as FARON, BEXCLEVY, BEXIGNUS, and HAEMATOKINE. These are among 4 currently registered trademarks in the portfolio.
What is Faron Pharmaceuticals Oy's trademark registration success rate?
Faron Pharmaceuticals Oy has a 31% trademark registration rate, with 4 out of 13 resolved applications resulting in successful registration. Currently, 0 applications are pending review.